

Lydia Giannitrapani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8543487/publications.pdf>

Version: 2024-02-01

85
papers

2,508
citations

257101

24
h-index

214527

47
g-index

87
all docs

87
docs citations

87
times ranked

4277
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort. <i>Internal and Emergency Medicine</i> , 2022, 17, 43-51.	1.0	3
2	SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3668.	1.8	14
3	Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population. <i>Journal of Infection</i> , 2022, 85, 174-211.	1.7	9
4	Response to the Letter to the editor regarding "Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma" by Jiong Lin. <i>Cancer Letters</i> , 2021, 500, 161-162.	3.2	0
5	Benign and malignant mimickers of infiltrative hepatocellular carcinoma: tips and tricks for differential diagnosis on CT and MRI. <i>Clinical Imaging</i> , 2021, 70, 33-45.	0.8	18
6	Hepatocellular Carcinoma: A Difficult Cancer to Treat. <i>Critical Reviews in Oncogenesis</i> , 2021, 26, 11-25.	0.2	2
7	NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response. <i>FASEB Journal</i> , 2021, 35, e21395.	0.2	4
8	The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma. <i>Cancer Letters</i> , 2021, 519, 250-262.	3.2	9
9	Potential Uses of Olive Oil Secoiridoids for the Prevention and Treatment of Cancer: A Narrative Review of Preclinical Studies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1234.	1.8	53
10	The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement?. <i>Nutrients</i> , 2021, 13, 4014.	1.7	18
11	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. <i>Metabolites</i> , 2020, 10, 392.	1.3	34
12	Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158792.	1.2	18
13	The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods. <i>BioMed Research International</i> , 2020, 2020, 1-7.	0.9	18
14	The Changing Epidemiology of Hepatocellular Carcinoma: Experience of a Single Center. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	15
15	Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma. <i>Cancer Letters</i> , 2020, 486, 8-17.	3.2	21
16	New landscapes and horizons in hepatocellular carcinoma therapy. <i>Aging</i> , 2020, 12, 3053-3094.	1.4	37
17	HepaDisk " A new quality of life questionnaire for HCV patients. <i>Digestive and Liver Disease</i> , 2019, 51, 1008-1015.	0.4	3
18	CEUS in the differential diagnosis between biliary sludge, benign lesions and malignant lesions. <i>Journal of Ultrasound</i> , 2018, 21, 119-126.	0.7	20

#	ARTICLE	IF	CITATIONS
19	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4.	0.6	291
20	Association Between <i>MICA</i> Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 274-282.	1.0	7
21	Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 226-232.	0.8	33
22	Hemophagocytic syndrome in a patient with disseminated tuberculosis: a case report. <i>Italian Journal of Medicine</i> , 2018, 12, 61.	0.2	1
23	Optimizing diagnostic approach to drug-induced liver injury. <i>Italian Journal of Medicine</i> , 2018, 12, 180-189.	0.2	2
24	Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 740-749.	1.9	16
25	Nontumorous Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of β -Blockers. <i>Medical Principles and Practice</i> , 2018, 27, 466-471.	1.1	9
26	<i>KIR2DL3</i> and the <i>KIR</i> ligand groups <i>HLA-A*24</i> and <i>HLA-C*2</i> predict the outcome of hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 768-775.	1.0	25
27	Case report: acute portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent adult. <i>Journal of Ultrasound</i> , 2017, 20, 161-165.	0.7	10
28	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 688-695.	1.9	124
29	Waiting-Time and Quality of Care Deserved to Patients with Early Stage Hepatocellular Carcinoma Undergoing RFA Treatment. <i>Annals of Hepatology</i> , 2017, 16, 699-701.	0.6	1
30	Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	13
31	An unusual Erdheim-Chester disease with orbital involvement: a case report. <i>Italian Journal of Medicine</i> , 2016, 10, .	0.2	0
32	The association of variants in <i>PNPLA3</i> and <i>GRP78</i> and the risk of developing hepatocellular carcinoma in an Italian population. <i>Oncotarget</i> , 2016, 7, 86791-86802.	0.8	16
33	Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid. <i>World Journal of Gastroenterology</i> , 2016, 22, 103.	1.4	17
34	Vitamin D and Osteoporosis in HIV/HCV Coinfected Patients: A Literature Review. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-7.	0.6	6
35	Effects of Steatosis on Hepatic Hemodynamics in Patients with Metabolic Syndrome. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 1545-1552.	0.7	11
36	Clinical course and management of acute and chronic viral hepatitis during pregnancy. <i>Journal of Viral Hepatitis</i> , 2015, 22, 515-523.	1.0	15

#	ARTICLE	IF	CITATIONS
37	Non invasive tools for the diagnosis of liver cirrhosis. World Journal of Gastroenterology, 2014, 20, 18131.	1.4	76
38	Variation in genes encoding for interferon β and ϵ in the prediction of HCV treatment-induced viral clearance. Liver International, 2014, 34, 1369-1377.	1.9	9
39	Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiologia Medica, 2014, 119, 215-221.	4.7	24
40	Nanotechnology applications for the therapy of liver fibrosis. World Journal of Gastroenterology, 2014, 20, 7242.	1.4	74
41	The Role of HSP70 in the Diagnosis of HCC. Forum on Immunopathological Diseases and Therapeutics, 2014, 5, 137-143.	0.1	0
42	Epidemiology, Diagnosis, and Non-Pharmacological Treatment of HCC. Forum on Immunopathological Diseases and Therapeutics, 2014, 5, 115-136.	0.1	0
43	Distribution of liver disease in a cohort of immigrants in Sicily: analysis of day-hospital admissions in a migration medicine unit. Infezioni in Medicina, 2014, 22, 200-5.	0.7	2
44	The health of irregular and illegal immigrants: analysis of day-hospital admissions in a department of migration medicine. Internal and Emergency Medicine, 2013, 8, 561-566.	1.0	13
45	Late-onset Sheehan's syndrome presenting with rhabdomyolysis and hyponatremia: a case report. Journal of Medical Case Reports, 2013, 7, 227.	0.4	11
46	Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients. Annals of Hepatology, 2013, 12, 740-748.	0.6	19
47	Long-term follow-up of hepatitis C virus-positive patients with persistently normal serum transaminases. Annals of Hepatology, 2013, 12, 36-43.	0.6	2
48	Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 2449.	1.4	53
49	Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection. International Journal of Infectious Diseases, 2012, 16, e397-e402.	1.5	34
50	Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected mediterranean subjects. BMC Infectious Diseases, 2012, 12, 192.	1.3	19
51	Minor Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients: Kelly Clamp Crushing Resection Versus Heat Coagulative Necrosis with Bipolar Radiofrequency Device. American Surgeon, 2011, 77, 1490-1495.	0.4	3
52	IL-6 \sim 174G/C Polymorphism and IL-6 Serum Levels in Patients with Liver Cirrhosis and Hepatocellular Carcinoma. OMICS A Journal of Integrative Biology, 2011, 15, 183-186.	1.0	50
53	COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. OMICS A Journal of Integrative Biology, 2011, 15, 383-392.	1.0	27
54	Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor- α , and Vascular Endothelial Growth Factor-A Genes, and Susceptibility to Hepatocellular Carcinoma. OMICS A Journal of Integrative Biology, 2011, 15, 193-196.	1.0	18

#	ARTICLE	IF	CITATIONS
55	Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein Ratio in Hepatocellular Carcinoma. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 267-272.	1.0	27
56	Minor hepatic resection for hepatocellular carcinoma in cirrhotic patients: Kelly clamp crushing resection versus heat coagulative necrosis with bipolar radiofrequency device. <i>American Surgeon</i> , 2011, 77, 1490-5.	0.4	3
57	Low-grade fever: how to distinguish organic from non-organic forms. <i>International Journal of Clinical Practice</i> , 2010, 64, 316-321.	0.8	14
58	Hepatocellular carcinoma: Comparison of two different periods at the same center. <i>European Journal of Internal Medicine</i> , 2010, 21, 127-130.	1.0	11
59	Genetic Determined Downregulation of Both Type 1 and Type 2 Cytokine Pathways Might Be Protective against Pancreatic Cancer. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 284-288.	1.8	17
60	Cyclooxygenase-2 Expression in Chronic Liver Diseases and Hepatocellular Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 293-299.	1.8	44
61	Prostaglandin E ₂ Receptors and COX Enzymes in Human Hepatocellular Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 300-308.	1.8	20
62	Reliability of the bright liver echo pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasaemia. <i>Clinical Radiology</i> , 2009, 64, 1181-1187.	0.5	19
63	Progressive visceral leishmaniasis misdiagnosed as cirrhosis of the liver: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 7265.	0.4	5
64	Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 927-933.	0.8	2
65	Circulating Levels of Adhesion Molecules in Chronic Kidney Disease Correlate with the Stage of Renal Disease and with C-Reactive Protein. <i>Archives of Medical Research</i> , 2007, 38, 534-538.	1.5	28
66	Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. <i>Liver International</i> , 2006, 26, 1119-1125.	1.9	46
67	Significance of Autologous Interleukin-6 Production in the HA22T/VGH Cell Model of Hepatocellular Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 268-275.	1.8	12
68	Sex Hormones and Risk of Liver Tumor. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 228-236.	1.8	241
69	Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 2563.	1.4	104
70	Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of β -catenin and inhibition of β -catenin-mediated transactivation. <i>International Journal of Molecular Medicine</i> , 2004, 13, 741.	1.8	10
71	Expression of IAPs and Alternative Splice Variants in Hepatocellular Carcinoma Tissues and Cells. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 289-293.	1.8	25
72	Expression of WISPs and of Their Novel Alternative Variants in Human Hepatocellular Carcinoma Cells. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 432-439.	1.8	47

#	ARTICLE	IF	CITATIONS
73	Leucocyte Interferon-alpha for Patients with Chronic Hepatitis C Intolerant to Other alpha-Interferons. <i>BioDrugs</i> , 2003, 17, 201-205.	2.2	10
74	Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment. <i>Intervirology</i> , 2003, 46, 35-42.	1.2	4
75	Extreme thrombocytosis as a sign of coeliac disease in the elderly: case report. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 897-900.	0.8	18
76	Different expression of HIP/PAP transcripts in human hepatoma cells. <i>Journal of Hepatology</i> , 2002, 36, 72.	1.8	0
77	Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 13-20.	1.8	252
78	Circulating IL-6 and sIL-6R in Patients with Hepatocellular Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 46-52.	1.8	49
79	Circulating E-selectin levels in chronic hepatitis C patients with normal or elevated transaminase before and after alpha-interferon treatment. <i>Inflammation</i> , 2001, 25, 101-108.	1.7	2
80	Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease. <i>Gut</i> , 2001, 49, 506-511.	6.1	60
81	Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2000, 126, 345-351.	1.2	15
82	Tissue Transglutaminase Autoantibodies in Patients with Non-Hodgkin's Lymphoma. <i>Digestion</i> , 2000, 62, 271-275.	1.2	15
83	Evidence of Transient IgA Anti-Endomysial Antibody Positivity in a Patient with Graves' Disease. <i>Digestion</i> , 1999, 60, 86-88.	1.2	18
84	Truncated Form of beta-Catenin and Reduced Expression of Wild-Type Catenins Feature HepG2 Human Liver Cancer Cells. <i>Annals of the New York Academy of Sciences</i> , 1999, 886, 212-216.	1.8	47
85	Comparative Responses to Three Different Types of Interferon- α in Patients with Chronic Hepatitis C. <i>Current Medical Research and Opinion</i> , 1998, 14, 235-241.	0.9	9